Idéal Investisseur
Français English
CAC 40 : Market closed
7 969,42 pts
-0.01%


Last updated : 30/10/2026 - 17h36 (last close)
Last close data
🏠 Home   ➤    Stock news

Amoéba Secures Emergency Authorization in Italy for its Biofungicide Axpera

Amoéba announced on Monday that it has obtained a 120-day emergency authorization in Italy for its biofungicide Axpera, aimed at combating basil downy mildew. This temporary authorization addresses a critical phytosanitary situation in a key crop of the Italian market.


Amoéba Secures Emergency Authorization in Italy for its Biofungicide Axpera

A Solution to a Destructive Disease

Basil downy mildew, caused by Peronospora belbahrii, is particularly destructive on fresh basil, a crop with very low or nonexistent commercial tolerance for symptoms. Under favorable conditions, the disease can affect 70% to 80% of the production and, in the most severe cases, destroy a crop within three to four days.

For several years, Italian producers have been facing particularly challenging disease pressure, exacerbated by the varietal sensitivity of Italian basil and favorable climatic conditions for the pathogen's development. Concurrently, the number of available phytosanitary active substances is decreasing annually, leading farmers to seek alternatives, particularly for organic producers, who account for 30% of the global market volume.

A Major Economic Stake for the Italian Market

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Italy plays a central role in the European basil market, particularly through the Genovese basil sector aimed at the fresh market and processing, especially for pesto production. The economic value of this crop far exceeds primary production, fueling a high-value-added chain that includes seeds, cultivation in protected and open fields, packaging, processing, and export.

From 2009 to 2023, the fresh basil-based pesto alla genovese sauce has seen a sustained annual growth of 13.7% globally. Food and beverage uses account for 71% of the market, while pharmaceutical and cosmetic applications make up 19%. Protecting basil from downy mildew is a major agronomic, economic, and quality challenge for Italian producers.

A Temporary Framework Pending Full Commercial Approval

The emergency authorization, supported by Italian basil producers' associations, was granted by the Italian Ministry of Health and allows the use of the biofungicide Axpera as a preventive treatment against basil downy mildew for a period of 120 days, from June 5 to October 2, 2026.

Jean-Marc Pétat, CEO of Green for Agro, an Amoéba subsidiary specializing in biosolutions, commented: 'Securing this 120-day emergency authorization in Italy marks a new step in the European deployment of our biofungicide. It addresses a concrete need in the sector in a strategic country for basil, faced with strong mildew pressure and consumer demand for disease control solutions that leave no residue.' This authorization comes in anticipation of obtaining a full marketing authorization for the product in Italy.



Sector Chimie › Biotech industrielle (enzymes, fermentation, biorecyclage, biosourcés)


Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext

Context

Period
  • Period: S1 2026
Key reported figures
  • Revenue: 0,1 millions d'euros
  • Quarterly revenue: 0,1 millions d'euros
  • Net income: -7,4 millions d'euros
  • 6,6 millions d'euros
Guidance from the release
  • Sur la base de ses ressources actuelles, de son plan d'affaires et de la lettre de soutien de son actionnaire de référence, Amoéba estime pouvoir faire face à ses obligations jusqu'au 31 décembre 2026.
Risks mentioned
  • Autorisation définitive d'AXPERA obtenue tardivement (fin juin 2026) après période d'utilisation des produits, affectant les ventes du semestre
  • Monétisation de la plateforme cosmétique dont ni la réalisation, ni le calendrier, ni le montant ne sont acquis à ce jour
  • Besoin de levée de fonds supplémentaire pour assurer continuité d'exploitation jusqu'au 30 septembre 2027 et financer plan de développement
Opportunities identified
  • Autorisation pérenne AXPERA obtenue en France en juin 2026 ouvre la voie à la commercialisation en plusieurs pays européens
  • Accord majeur signé avec Syngenta pour distribution exclusive de la solution en céréales dans 27 pays UE, premiers lancements commerciaux attendus Q3 2028
  • Extension de l'accord de distribution Koppert jusqu'en juin 2031 et potentiel de monétisation de la plateforme cosmétique Willa™ dès 2027
Outlook / guidance
  • Expected revenue: 1,5 millions d'euros
  • Management commentary: Building on the outcomes of the various strategic initiatives undertaken since 2023, Amoéba will be able to leverage the ramp-up of its contracts in the agricultural sector from 2027 onwards to achieve revenue of between €1 million and €2 million.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours